A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Trial Profile

A Phase 1 Open-Label Study to Evaluate the Effect of CYP450 and P-gp Inhibition and Induction on the Pharmacokinetics of Pomalidomide (CC-4047) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 22 Sep 2014

At a glance

  • Drugs Pomalidomide (Primary) ; Carbamazepine; Fluvoxamine; Ketoconazole
  • Indications Bipolar disorders; Epilepsy; Graft-versus-host disease; Multiple myeloma; Myelofibrosis; Obsessive-compulsive disorders; Pancreatic cancer; Seborrhoeic dermatitis; Small cell lung cancer; Social phobia; Systemic scleroderma; Waldenstrom's macroglobulinaemia
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 08 Nov 2012 New trial record
    • 01 Nov 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top